Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead Maintaining Lead Position In Hepatitis C, While Idenix Is Starting Over

Executive Summary

Gilead and AbbVie are seen as running neck-and-neck to bring the first all-oral combo of direct-acting antivirals to market in HCV, but Gilead’s regimen is expected to win a larger market share. Idenix is starting over in the nucleoside space, but expects to bring a uridine-based “nuc” into clinical development by mid-year.

You may also be interested in...

Still Bullish On HCV, Idenix Also Plans To Focus On Oncology, Other Infectious Diseases

New Chief Scientific Officer Jacques Dumas says the clinical-stage firm intends to leverage its expertise in nucleoside discovery to create drug candidates for cancer and other infectious diseases. Concurrent with its drug development in hepatitis C, Idenix plans to address these other indications with the help of partners.

Janssen Bets On Simeprevir For HCV In China; Partners With Hepatology Society

It may take four to five years for next-generation oral hepatitis C therapies to take hold in China, and Johnson & Johnson subsidiary Janssen Inc. isn’t wasting any time stepping up efforts to increase disease awareness via partnerships.

A Closer Look: Roche’s Move On Danoprevir Shines Light On Innovation Strategy In China

Roche Pharmaceuticals Asia Pacific Head Luke Miels talks to PharmAsia News about the company’s recent deal with Ascletis, its thinking on China’s hepatitis C market and additional opportunities for out-licensing.

Related Content


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts